Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Compass Therapeutics (CMPX) Accumulated Depreciation & Amortization (2023 - 2025)

Compass Therapeutics' Accumulated Depreciation & Amortization history spans 3 years, with the latest figure at $6.6 million for Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $6.6 million; the TTM value through Sep 2025 reached $6.6 million, changed N/A, while the annual FY2024 figure was $6.4 million, 1.5% up from the prior year.
  • Accumulated Depreciation & Amortization for Q3 2025 was $6.6 million at Compass Therapeutics, up from $6.5 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $6.6 million in Q3 2025 and bottomed at $5.8 million in Q1 2023.
  • The 3-year median for Accumulated Depreciation & Amortization is $6.4 million (2024), against an average of $6.3 million.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 10.62% in 2024 against a maximum downside of 1.5% in 2024.
  • A 3-year view of Accumulated Depreciation & Amortization shows it stood at $6.3 million in 2023, then increased by 1.5% to $6.4 million in 2024, then rose by 4.07% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Accumulated Depreciation & Amortization are $6.6 million (Q3 2025), $6.5 million (Q1 2025), and $6.4 million (Q4 2024).